To read the full story, subscribe or sign in.

Vectura's LAMA Starts Phase III as Part of Novartis COPD Combo

May 11, 2010

Today's news in brief

BioWorld briefs for July 31, 2026.

Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors

Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...

Silhouette illustration of DNA gene editing

Death in Chinese gene-editing trial exposes ethical fault lines

BioWorld

The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...

Seed funding at Adjuvia to treat mitochondrial dysfunction

BioWorld Science

Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...

Replimune’s RP-1 for melanoma wins over FDA adcom

BioWorld

Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...